Philip Morris Raises Full-Year Adjusted EPS Guidance, Launches ZYN ULTRA
PM sits 20% above its 52-week low of $142.11.
Summary
Philip Morris International updated its full-year adjusted EPS guidance upwards and announced the launch of ZYN ULTRA, a new nicotine pouch product, alongside a non-cash impairment charge for its Canadian affiliate.
Key Events · Earnings and Guidance · PM
-
Full-Year Adjusted EPS Guidance Raised
The company updated its 2026 full-year adjusted diluted EPS forecast to a range of $8.31 to $8.46, representing a projected increase of 10.2% to 12.2% versus $7.54 in 2025. This is a significant increase from the previous guidance of $7.56 to $7.71 communicated on April 22, 2026.
-
Non-Cash Impairment Charge
Philip Morris International expects to record a non-cash impairment charge of approximately $500 million (33 cents of diluted EPS) in the second quarter of 2026, related to its investment in its deconsolidated Canadian affiliate, RBH.
-
ZYN Portfolio Expansion
The company announced the launch of ZYN ULTRA, new 9mg and 11mg moist nicotine pouch variants, in the U.S. this month. These products will be positioned at a lower list price-per-pouch than the existing dry ZYN portfolio.
Analysis · PM · Manufacturing
Philip Morris International significantly increased its full-year adjusted diluted EPS forecast, signaling stronger performance expectations. This positive revision is partially offset by a non-cash impairment charge related to its Canadian affiliate, RBH. The company also announced a strategic expansion of its ZYN nicotine pouch portfolio with new, higher-strength products, aiming to optimize pricing and expand market reach in the growing smoke-free category.
At the time of this filing, PM was trading at $170.80 on NYSE in the Manufacturing sector, with a market capitalization of approximately $269.1B. The 52-week trading range was $142.11 to $193.05. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.